• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脊髓灰质炎

Poliomyelitis

作者信息

Wolbert Jonathan G., Rajnik Michael, Swinkels Helena M., Higginbotham Karla

机构信息

PBCGME

Uniformed Service University of the Health Sciences

PMID:32644370
Abstract

Poliomyelitis, or polio, is an infection transmitted via the fecal-oral and oral-oral routes by the poliovirus. Today, polio primarily affects children younger than 5 in countries with poor water, sanitation, and hygiene infrastructure. While extremely rare outside these areas, polio presents a risk to populations with low vaccination rates, including in industrialized nations. The 2014 declaration deeming the global spread of polioviruses a public health emergency of international concern under the International Health Regulations remains in place.[WHO. Vaccine Position] Previously one of the most feared diseases in the world, polio caused widespread morbidity and mortality in children during multiple epidemics between the 1900s and 1960s. The incidence of polio began to decline following the development of the injectable polio vaccine (IPV) and oral polio vaccine (OPV). Intensified worldwide vaccination efforts starting in the 1980s by the World Health Organization (WHO) and partners under the Global Polio Eradication Initiative (GPEI) have almost completely eradicated the disease. Vaccination protocols worldwide now recommend administering at least 3 doses of IPV (IPV-only schedule) or at least 3 doses of bivalent OPV plus at least 2 doses of IPV (combined OPV-IPV schedule). The latter is recommended in countries where poliovirus incidence rates remain unchanged or are at risk of increasing. See StatPearls' companion article "Polio Vaccine" for more information on polio vaccinations. Healthcare professionals must maintain a high index of suspicion to diagnose acute poliomyelitis in patients who present with new-onset paralysis following a viral prodrome and are living in an endemic region or under-vaccinated population. The presentation of polio is highly variable, ranging from asymptomatic to a transient flu-like viral illness to paralysis, quadriplegia, and even respiratory failure and death. Many polio survivors experience a poor quality of life. Alternate diagnoses must be considered as polio is rare, and other more common diseases and conditions can present similarly. In particular, acute flaccid myelitis (AFM) presents with a polio-like syndrome. This condition is caused by epidemic enteroviral infections, most commonly enterovirus D68. As no antiviral treatment for acute poliomyelitis exists, prevention is critical. Paralytic deficits are often permanent, resulting in chronic pain, deformities, weakness, and eventual osteoporosis and fragility fracture. Between 25% and 40% of the estimated 12 to 20 million polio survivors worldwide will also develop postpolio syndrome (PPS). A diagnosis of PPS requires new-onset, progressive muscle weakness or fatiguability, mental fatigue, or pain in a patient diagnosed with poliomyelitis up to 40 years prior. PPS is not contagious and is rarely life-threatening, but it often affects patients' independence and quality of life. While the near eradication of polio represents a tremendous achievement for global public health, multiple challenges and delays remain. Vaccine-derived polioviruses (VDPVs) revert or recombine to wild-type neurovirulence and transmissibility, causing outbreaks and distrust in vaccination programs. Poliovirus typically escapes early detection; most infections are asymptomatic, and the characteristic paralysis occurs in a small minority of those it infects.[CDC. Polio_HCP] Delays in detecting circulating wild poliovirus (WPV) and VDPVs pose a significant risk to eradication efforts. Political unrest or indecision and declining or competing interests threaten efforts to eradicate the disease. Recent polio cases and the discovery of poliovirus in wastewater in industrialized nations emphasize that, until completely eradicated, polio remains a global risk.[GPEI. Polio Eradication] Clinicians should suspect polio in patients with acute-onset flaccid paralysis, decreased or absent tendon reflexes, and without sensory or cognitive deficits. to ensure appropriate diagnostic testing, surveillance, and public health follow-up at.[CDC. Polio_Clinical]

摘要

脊髓灰质炎,简称小儿麻痹症,是一种由脊髓灰质炎病毒通过粪口途径和口口途径传播的感染性疾病。如今,脊髓灰质炎主要影响水、环境卫生和个人卫生基础设施较差国家中5岁以下的儿童。虽然在这些地区以外极为罕见,但脊髓灰质炎对疫苗接种率较低的人群构成风险,包括工业化国家的人群。2014年宣布将脊髓灰质炎病毒的全球传播视为《国际卫生条例》规定的国际关注的突发公共卫生事件,这一认定仍然有效。[世界卫生组织。疫苗立场]脊髓灰质炎曾是世界上最令人恐惧的疾病之一,在20世纪初至60年代的多次疫情中,它在儿童中造成了广泛的发病和死亡。随着注射用脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎疫苗(OPV)的研制成功,脊髓灰质炎的发病率开始下降。20世纪80年代起,世界卫生组织(WHO)及其合作伙伴在全球根除脊髓灰质炎行动(GPEI)下加强了全球疫苗接种工作,几乎完全根除了这种疾病。现在,全球的疫苗接种方案建议至少接种3剂IPV(仅IPV方案)或至少3剂二价OPV加至少2剂IPV(联合OPV-IPV方案)。在脊髓灰质炎病毒发病率保持不变或有上升风险的国家,推荐采用后者。有关脊髓灰质炎疫苗接种的更多信息,请参阅StatPearls的配套文章“脊髓灰质炎疫苗”。对于在病毒前驱症状后出现新发麻痹、生活在流行地区或疫苗接种不足人群中的患者,医疗保健专业人员必须保持高度怀疑,以诊断急性脊髓灰质炎。脊髓灰质炎的表现高度可变,从无症状到短暂的流感样病毒疾病,再到麻痹、四肢瘫痪,甚至呼吸衰竭和死亡。许多脊髓灰质炎幸存者生活质量较差。由于脊髓灰质炎罕见,必须考虑其他诊断,其他更常见的疾病和病症可能有类似表现。特别是,急性弛缓性脊髓炎(AFM)表现为类似脊髓灰质炎的综合征。这种病症由流行性肠道病毒感染引起,最常见的是肠道病毒D68。由于不存在针对急性脊髓灰质炎的抗病毒治疗方法,预防至关重要。麻痹性缺陷通常是永久性的,会导致慢性疼痛、畸形

相似文献

1
Poliomyelitis脊髓灰质炎
2
Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.用于预防脊髓灰质炎的序贯灭活脊髓灰质炎疫苗(IPV)和口服脊髓灰质炎减毒活疫苗(OPV)
Cochrane Database Syst Rev. 2019 Dec 5;12(12):CD011260. doi: 10.1002/14651858.CD011260.pub2.
3
Eradicating polio: how the world's pediatricians can help stop this crippling illness forever.消灭脊灰:全世界的儿科医生如何助力永远终结这种致残疾病
Pediatrics. 2015 Jan;135(1):196-202. doi: 10.1542/peds.2014-3163.
4
Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015.2014年1月至2015年3月全球疫苗衍生脊髓灰质炎病毒最新情况
MMWR Morb Mortal Wkly Rep. 2015 Jun 19;64(23):640-6.
5
Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.三价口服脊髓灰质炎疫苗停用和灭活脊髓灰质炎疫苗引入-全球,2016 年。
MMWR Morb Mortal Wkly Rep. 2016 Sep 9;65(35):934-8. doi: 10.15585/mmwr.mm6535a3.
6
Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses.关于脊髓灰质炎病毒所致麻痹性脊髓灰质炎快速消除及最终全球根除的观点
Eur J Epidemiol. 1991 Mar;7(2):95-120. doi: 10.1007/BF00237353.
7
Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.脊髓灰质炎疫苗。全球根除脊髓灰质炎的进展以及美国常规免疫接种建议的变化。
Pediatr Clin North Am. 2000 Apr;47(2):287-308. doi: 10.1016/s0031-3955(05)70208-x.
8
Guidance for Assessment of Poliovirus Vaccination Status and Vaccination of Children Who Have Received Poliovirus Vaccine Outside the United States.美国境外脊髓灰质炎疫苗接种状况评估及已接种脊髓灰质炎疫苗儿童的疫苗接种指南。
MMWR Morb Mortal Wkly Rep. 2017 Jan 13;66(1):23-25. doi: 10.15585/mmwr.mm6601a6.
9
Environmental Surveillance Complements Case-Based Surveillance of Acute Flaccid Paralysis in Polio Endgame Strategy 2019-2023.环境监测对脊灰终结战略 2019-2023 年基于病例的急性弛缓性麻痹监测的补充作用。
Appl Environ Microbiol. 2020 Jul 20;86(15). doi: 10.1128/AEM.00702-20.
10
Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.2013 - 2016年全球灭活脊髓灰质炎疫苗的引入及三价口服脊髓灰质炎疫苗向二价口服脊髓灰质炎疫苗的转换
MMWR Morb Mortal Wkly Rep. 2015 Jul 3;64(25):699-702.